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Abstract
Background: The use of pretargeting technology for cancer imaging and treatment has made
significant progress in the last few years. This approach takes advantage of the fact that biotin binds
strongly to proteins avidin and streptavidin. Thus, a non-toxic tumor cell specific antibody is
conjugated with avidin/streptavidin, and is administered to patients. After the antibody binds to
tumor cells (usually 24–48 h); a clearing agent is given to remove the residual circulating antibodies
in blood. Lastly, a toxic biotin-radioisotope conjugate is administered. Due to the small size of the
biotin-radioisotope molecule and tight binding between biotin and avidin/streptavidin, the biotin-
radioisotope rapidly binds to tumor cells with high specificity. CC-1065 (1) is one of a few classes
of extremely potent antitumor agents, and a biotinalyted CBI-bearing CC-1065 analogue is a
promising candidate to be used in the pretargeting technology to treat cancer.
Results: A biotinalyted CBI-bearing CC-1065 analogue, 6, was synthesized. The IC50 of 6 was 0.7
nM against U937 cells. Compound 6 caused apototsis of U937 cells.
Conclusions: For the first time, a biotinalyted CBI-bearing CC-1065 analogue, 6, was synthesized.
The biotinylated 6 can serve as a model compound to explore the usefulness of non-radioactive
small molecule anticancer drugs in the pretargeting strategy for cancer imaging and therapy.
Background
Anticancer drugs generally act on metabolically active or
rapidly proliferating cells, and cannot distinguish be-
tween cancer and normal cells; thus, toxicities to normal
cells limit the dose of drugs that can be given to patients.
Therefore, much research has focused on development of
more specific therapeutic strategies to reduce toxicity to
normal cells. One of these strategies is monoclonal anti-
body-directed pretargeting technology. The use of pretar-
geting technology for cancer imaging and treatment has
made significant progress in the last few years [1–6]. This
approach takes advantage of the fact that biotin binds
strongly to proteins avidin and streptavidin [7,8]. Thus, a
non-toxic tumor cell specific antibody is conjugated with
avidin/streptavidin, and is administered to patients. After
the antibody binds to tumor cells (usually 24–48 h); a
clearing agent is given to remove the residual circulating
antibodies in blood. Lastly, a toxic biotin-radioisotope
conjugate is administered. Due to the small size of the bi-
otin-radioisotope molecule and tight binding between bi-
otin and avidin/streptavidin, the biotin-radioisotope
rapidly binds to tumor cells with high specificity. This ap-
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proach decouples the lengthy antibody to target process
and the administration of a toxic moiety, but takes full ad-
vantage of both the high target specificity of the antibody
and the favorable pharmacokinetics of a small toxic mol-
ecule. While progress using radioisotopes in this approach
has been achieved, few reports on using a potent non-ra-
dioactive small molecule anticancer drug for this purpose
have been seen. A potent non-radioactive small molecule
drug for this approach is potentially better than a radioi-
sotope because the latter is much more difficult to handle
than a non-radioactive chemical agent.
CC-1065 (1) is one of a few classes of extremely potent an-
titumor agents [9–12]. It binds to double-stranded B-
DNA within the minor groove with the sequence prefer-
ence for 5'-d(A/GNTTA)-3' and 5'-d(AAAAA)-3', and
alkylates the N3 position of the 3'-adenine with its left-
hand CPI segment [13–15]. CC-1065 also inhibits gene
transcription by interfering with binding of the TATA box
binding protein to its target DNA [16]. Despite its high
potency and broad spectrum of antitumor activity, CC-
1065 cannot be used in humans because it causes delayed
death in experimental animals [17]. To pursue com-
pounds retaining the potent antitumor activity but devoid
of the toxic side effects of the parent compound, many
CC-1065 analogues have been synthesized and tested
[18–26].
Because of the high potency, broad spectrum of antitumor
activity, and novel mechanism of action, the CC-1065
class of compounds has the potential to be useful in the
pretargeting approach. Herein, we report synthesis and
preliminary cytotoxicity study of a CBI-biotin CC-1065
analogue designed as a model compound to explore its
use in the pretargeting approach for cancer imaging and
therapy.
Results and discussion
Target compound 6 was synthesized using two methods.
The synthesis using Method A is illustrated in Scheme 1.
Alternatively,  6 was also synthesized using Method B
(Scheme 2).
Using Method A, a radioisotope-labeled N-hydroxysuc-
cinimidobiotin can be conveniently added at the last step
to synthesize radioisotope-labeled materials for metabolic
and other biological studies. Because of the lengthy proc-
ess and low overall yield in the synthesis of starting mate-
rial  2, Method B is more economical for large-scale
synthesis.
The cytotoxicity of 5, 6 and doxorubicin, used as a positive
control, were tested against U937 leukemia cells, and the
results were presented in Table 1. The biotinylated 6
(IC50: 0.7 nM) is approximately 7-fold less toxic than its
precursor 5 (IC50: 0.09 nM). However, 6 is still much
more potent than doxorubicin (IC50: 100 nM). As ob-
served for other CC-1065 class of compounds [26,28,29],
6 caused DNA fragmentation and the cells died by apop-
tosis (data not shown).
Conclusions
The preliminary in vitro studies suggest that a biotin moi-
ety can be incorporated into a CBI-bearing CC-1065 ana-
logue to produce a potent biotinylated agent. When a
biotin-nuclide conjugate is used, the conjugate does not
need to be internalized to destroy the tumor cells. Howev-
er, for a biotinylated CC-1065 analogue to work in this
pretargeting strategy, the biotinylated drug must first bind
to the avidin/streptavidin-antibody conjugate on the tu-
mor cell surface. The drug must then gain entry to the cell
to act by binding to DNA. Whether compound 6 can be
internalized, after binding to the avidin/streptavidin-anti-
body conjugate on the tumor cell surface, is unclear at the
present time. We will report experimental results address-
ing this question in due course. Nevertheless, we think
that the biotinylated 6 can serve as a model compound to
explore the usefulness of non-radioactive small molecule
Table 1: Cytotoxicity of compounds 5, 6, and doxorubicin against 
U937 leukemia cells in vitroa
Compd. IC50 (nM)b
5 0.09
6 0.7
Doxorubicin 100
aCells were incubated with drugs for 48 h and the experiments were 
performed according to our previously published method [26]; bIC50 
values are defined as the minimal drug concentration necessary to 
inhibit incorporation of [3H]thymidine by 50%, and are the averages 
of three experiments.
Figure 1
Structure of CC-1065
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anticancer drugs in the pretargeting strategy for cancer im-
aging and therapy.
Materials and methods
Method A
3-[(5-Amino-1H-indol-2'-yl)carbonyl]-1-(chlorom-ethyl)-5-hydroxy-1, 
2-dihydro-3H-benz [e]indole (5).
A solution of CBI [27], 2, (15 mg, 76 µmol) in 3 mL of
ethyl acetate saturated with anhydrous hydrogen chloride
was stirred at room temperature for 30 min in the dark.
The suspension was concentrated in vacuo to give interme-
diate 3. Without further purification, the latter was dis-
solved in DMF (0.5 mL) and treated with 5-nitroindole-2-
carboxylic acid (18 mg, 87 µmol) and 1-(3-dimethylami-
nopropyl)-3-ethylcarbodiimide (EDCI, 43 mg, 225
µmol). The reaction mixture was stirred at room tempera-
ture overnight and purified by thin layer chromatography
eluting with 50% hexane in ethyl acetate to give 4. With-
out further purification, the latter was dissolved in a solu-
tion containing DMF (0.5 mL) and ethyl acetate (5 mL).
Pd/C (10%, 10 mg) was added and the reaction mixture
was hydrogenated for 1 h at ambient temperature under 1
atm pressure. The product was filtered, and the filter cake
was washed with methanol (20 mL). The solvent was re-
moved in vacuo, and ether was added. The solid was fil-
tered, and washed to afford 5 (13 mg, 44% yield from 2).
mp>300°C. 1H NMR (DMF-d7, ppm): 11.16 (brs, 1 H,
NH), 10.46 (s, 1 H, OH), 8.24–6.81 (m, 9 H, Ar-H), 4.84–
4.79 (dd, 1 H, J = 9.3, 11.1 Hz, N HH), 4.71–4.67 (m, 3
H, NCH H, NH2), 4.31–4.21 (m, 1 H, CH2ClC HCH2N),
4.18–4.12 (dd, 1 H, J = 1.0, 18.7 Hz, ClC HH), 3.93–3.88
(dd, 1 H, J = 7.9, 11.2 Hz, ClCH H). HRMS calcd for
C22H18ClN3O2 391.1088 found 391.1068.
3-[5-(Biotin-amino)-1H-indol-2'-yl]carbonyl]-1-(chloromethyl)-5-hy-
droxy-1, 2-dihydro-3H-benz [e]-indole(6).
To a solution of 5 (2 mg, 5.1 µmol) in DMF (0.2 mL) was
added N-hydroxysuccinimidobiotin (5.2 mg, 15.3 µmol),
and the solution was stirred for 48 h at ambient tempera-
ture. The product was purified by thin layer chromatogra-
phy eluting with ethyl acetate and methanol (4/1, v/v) to
give 6 (1.5 mg, 48%) as a gray solid. 1H NMR (DMF-d7,
ppm): 11.56 (brs, 1 H, NH), 10.55 (s, 1 H, OH), 9.91 (s,
1 H, NH), 8.25-7.21 (m, 9 H, Ar-H), 6.32 (s, 1 H, biotin
NH), 6.24 (s, 1 H, biotin NH), 4.90-4.85 (t, 1 H, J = 11.0
Hz, N HH), 4.74-4.70 (dd, 1 H, J = 2.0, 11.0 Hz, NH H),
4.49-4.45 (m, 1 H, biotin H), 4.32-4.28 (m, 2 H, ClCH2C
HCH2, biotin H), 4.14-4.10 (dd, 1 H, J= 3.6, 11.1 Hz, C
HHCl), 3.96-3.91 (dd, 1 H, J = 7.8, 11.1 Hz, CH HCl),
3.20-3.27 (m, 1 H, biotin H), 2.45-2.41 (t, 2 H, J = 7.7 Hz,
COCH2), 1.8-1.5 (m, 6 H, CO(CH2)3). HRMS calcd for
C32H32ClN5O4S (M + Na+) 640.1761, found 640.1759.
Method B
5-(Biotin-amino)indole-2-carboxylic acid (9)
To a solution of 7 (60 mg, 294 µmol) in DMF (1 mL) was
added N-hydroxysuccinimidobiotin (110 mg, 323 µmol)
and the solution was stirred overnight at room tempera-
ture. The product was purified by flash chromatography
eluting first with ethyl acetate followed by acetone. The
solvent was removed in vacuo. Without further purifica-
tion, methanol (5 mL) was added followed by 1 N NaOH
(2 mL). The reaction mixture was stirred overnight at
room temperature. The precipitate was filtered, and the
filtrate was neutralized using 20% HCl. The precipitate
was filtered, and the filter cake was washed with water.
The product was dried in air to afford 49 mg (41% yield
from 7) of gray solid. 1H NMR (DMSO-d6, ppm): 12.55
(brs, 1 H, COOH), 11.60 (s, 1 H, NH), 9.70 (s, 1 H, NH),
7.98-7.02 (m, 4 H, Ar-H), 6.39 (s, 1 H, biotin NH), 6.31
(s, 1 H, biotin NH), 4.33-4.29 (t, 1 H, J = 7.5 Hz, C4'-H),
4.17-4.13 (m, 1 H, C8'-H), 3.14-3.11 (m, 1 H, C5'-H),
2.85-2.81 (dd, 1 H, J = 5.2, 12.7 Hz, C7'-HH), 2.60-2.57
(d, 1 H, J = 12.1 Hz, C7'-H H), 2.32-2.28 (t, 1 H, J = 7.4
Hz, CH2CO), 1.70-1.30 (m, 6 H, (CH2)3CH2CO). HRMS
calcd for C19H23N4O4S (M + H+) 403.1440 found
403.143 5.
To a solution of 3 (from 15 mg of CBI) in DMF (1 mL) was
added 9 (30 mg, 73 µmol) and EDCI (44 mg, 230 µmol)
sequentially, and the reaction mixture was stirred over-
night at room temperature. The product was purified by
thin layer chromatography eluting first with ethyl acetate
followed by ethyl acetate and methanol (4/1, v/v). The
Figure 2
Synthesis of 6 (Method A)
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solvent was removed in vacuo, and ether was added. The
solid was filtered, and washed with ether to give 17 mg
(37% yield) of 6, whose NMR spectrum is identical to the
product made using Method A.
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Synthesis of 6 (Method B)
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